Mendus presents an update on the use of its DCOne platform to source high-quality NK cell therapies at the 8th Annual Innate Killer Summit finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds. | March 30, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds. | March 29, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds. | March 28, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds. | March 27, 2023